Publications by authors named "V Libois"
Article Synopsis
- - Patients with oligometastatic prostate cancer (having up to 5 metastases) generally have a better prognosis than those with more extensive disease, making this a crucial area for treatment investigation.
- - The study investigates whether combining stereotactic body radiotherapy (SBRT) with the immune checkpoint inhibitor durvalumab can improve progression-free survival in these patients compared to SBRT alone.
- - This multicenter phase II trial will evaluate various outcomes, including quality of life and immune response, by enrolling 96 participants over three years, aiming to provide insights into better treatment strategies for prostate cancer.
Immunotherapy occupies a growing place in urologic oncology, mainly for kidney and bladder cancers. On the basis of encouraging preclinical work, the combination of immunotherapy with radiotherapy aims to increase the tumor response, including in metastatic tumors, which raises many hopes, which this article reviews.
View Article and Find Full Text PDFWe report the case of a 57-year-old woman who presented with local invasion of the anal canal by mucinous adenocarcinoma, the malignant transformation of a long-term preexisting retrorectal tailgut cyst. This progression is infrequent and justifies preemptive surgical treatment of retrorectal cysts.
View Article and Find Full Text PDFArticle Synopsis
- Stereotactic body radiotherapy (SBRT) provides high doses of radiation to vertebral metastases while protecting the spinal cord, and a new method using anti-CEA PET imaging enhances target volume determination for patients with metastatic breast or thyroid cancer.
- In a study involving eight patients, iPET was performed alongside MRI and PET-CT scans, identifying more vertebral lesions than traditional methods and affecting clinical target volume (CTV) delineation in 70% of cases.
- The findings suggest that iPET improves mapping of affected vertebral segments, offering valuable additional information for planning effective SBRT treatments in cases of metastatic vertebral disease.
Article Synopsis
- - Oligometastatic prostate cancer (PCa) is being researched heavily with new PET tracers like F-choline and Ga-PSMA, showing promise in treatment by identifying limited metastases.
- - Treatment options like Stereotactic Body Radiation Therapy (SBRT) and lymph node dissection have demonstrated positive outcomes, including PSA response, lower toxicity, and benefits like delaying androgen deprivation therapy.
- - Despite promising findings, particularly for hormone-sensitive cases, there's limited data on treating oligoprogressive metastatic castration-resistant PCa, prompting ongoing studies and updated recommendations from key medical organizations to favor metastasis-directed therapies over observation.